The rise of GLP-1 drugs for weight loss has been nothing short of remarkable, with a staggering 11% of U.S. adults now reporting their use. But this trend has also brought to light a critical issue: the safety of these medications when accessed through telehealth companies. Leslie Gammon's harrowing experience is a stark reminder of the potential risks. She followed the dosing instructions from two different telehealth companies, only to suffer a GLP-1 overdose that landed her in the hospital.
What makes this case particularly concerning is the lack of oversight in the telehealth setting. While GLP-1 overdoses can occur after in-person appointments, the safety checks and frameworks in place at doctors' offices and pharmacies are often absent in the virtual realm. Dr. Fatima Syed, an associate professor of medicine at Duke University, emphasizes the importance of clinical oversight for weight management, stating, 'Your body and your weight deserve the same clinical oversight.'
The issue extends beyond individual cases. The National Poison Data System from America's Poison Centers reports a 1,500% increase in calls related to GLP-1 overdoses and side effects from 2019 to 2025. This trend is particularly alarming given that compounded GLP-1 drugs, which are cheaper and often offered by telehealth companies, are not reviewed by the FDA for safety. Patients may be taking 10 times the recommended dose due to confusing measurement units, leading to severe side effects.
The Alliance for Compounded Pharmacies has called for stronger oversight and transparency in sourcing and formulation, while preserving access to legitimate compounding practices. Both Novo Nordisk and Eli Lilly, the makers of brand-name GLP-1 drugs, have expressed grave concerns about the safety of mass-compounded knockoffs. This highlights the need for patients to understand the difference between FDA-approved drugs and compounded versions.
In my opinion, the rise of GLP-1 drugs through telehealth companies has brought to light a critical issue of oversight and safety. While these medications can be effective for weight loss, the lack of clinical oversight in the telehealth setting poses a significant risk to patients. It is crucial for patients to choose companies that offer easy access to medical professionals and to understand the differences between FDA-approved drugs and compounded versions. The future of GLP-1 drugs in the telehealth space depends on addressing these safety concerns and ensuring that patients receive the necessary clinical oversight.
